Ekso Bionics (Nasdaq: EKSO), manufacturer of the Ekso Indego Personal exoskeleton, reported lower revenue numbers for its second quarter in a July 28 earnings call. “While there was abnormal weakness in the second quarter, in large part due to what we believe are short-term delays in completing some multi-device enterprise health sales, we are working…
Ekso Bionics ‘Working to Get Back on Track’ After Lower Second-Quarter Earnings Report
Ekso Bionics Q1 Earnings: Partnerships with NSM, Bionic P&O Expected to Grow Personal Health Products Segment This Year
National Seating & Mobility was announced as the exclusive CRT distributor of the Ekso Indego Personal exoskeleton in February.
New partnerships with national Complex Rehab Technology (CRT) and prosthetics/orthotics providers are expected to grow Ekso Bionics’ Personal Health Products segment for 2025, the company announced during its May 5 earnings call. Ekso Bionics (Nasdaq: EKSO) reported earnings results for the three months ending on March 31, 2025, while also commenting on what the company…
Ekso Bionics to Focus on Indego Personal Exoskeleton Expansion Through CRT, DME Channels
The company shared its plans during a March 3 earnings call.
In an earnings call covering its 2024 full-year results, executives from Ekso Bionics (Nasdaq: EKSO) described the company’s plans to get its Ekso Indego Personal exoskeleton into the hands of more patients. “Revenue of $17.9 million was down from $18.3 million for the same period in 2023,” Ekso Bionics CFO Jerome Wong said, in describing…